TSX:TECK.B
TSX:TECK.BMetals and Mining

Teck Resources (TSX:TECK.B) Valuation Check After Recent Share Price Momentum

Teck Resources (TSX:TECK.B) is back on many investors’ radar after recent share price moves, with the stock closing at CA$68.46 and showing double digit returns over the past month and past 3 months. See our latest analysis for Teck Resources. The recent 10.5% 1 month share price return and 16.8% 3 month share price return suggest momentum is building again, while the 12.9% 1 year total shareholder return and 194.6% 5 year total shareholder return point to a stock that has rewarded patient...
TSX:EDV
TSX:EDVMetals and Mining

Endeavour Mining (TSX:EDV) Is Up 9.8% After Gold’s Safe-Haven Bid Intensifies Amid Geopolitical Shock – Has The Bull Case Changed?

In early January 2026, Endeavour Mining drew fresh attention after a past spike in geopolitical instability, including the capture of Venezuelan president Nicolás Maduro by US forces, pushed investors toward gold as a perceived safe-haven asset. This renewed focus on gold highlighted Endeavour Mining’s role as a multi-asset West African producer whose fortunes are closely tied to movements in the underlying gold price. We’ll now examine how this heightened geopolitical risk backdrop, and...
XTRA:DHL
XTRA:DHLLogistics

Is Deutsche Post (XTRA:DHL) Still Attractive After Strong 1‑Year Rally And Western Union Deal?

If you are wondering whether Deutsche Post is still fairly priced after its recent run, or if there is value left on the table, this article walks you through what the current market price might be implying. With the share price at €48.06 and returns of 2.8% over 7 days, 4.7% over 30 days, 2.5% year to date, 48.6% over 1 year, 45.7% over 3 years and 36.7% over 5 years, many investors are asking whether the recent performance already reflects the key drivers of value. Recent coverage has...
NYSE:BKH
NYSE:BKHIntegrated Utilities

How Investors Are Reacting To Black Hills (BKH) Completing Its Ready Wyoming Grid Expansion Project

Black Hills Corp. has completed and energized its 260-mile, US$350 million Ready Wyoming electric transmission expansion, which went into service in December 2025 and now links its South Dakota and Wyoming electric systems. This project is expected to enhance grid resiliency, support local economic growth, and recover most of its cost through a Wyoming Transmission Rider, with the balance addressed in future base rate reviews. Next, we’ll consider how the Ready Wyoming project’s long-term...
NYSE:WEC
NYSE:WECIntegrated Utilities

A Look At WEC Energy Group (WEC) Valuation As Earnings Slow And Illinois Rate Cases Draw Focus

WEC Energy Group (WEC) is coming up on its fourth quarter earnings report, with analysts expecting earnings of $1.37 per share, a 4.2% decline, just as fresh Illinois rate case filings sharpen regulatory focus. See our latest analysis for WEC Energy Group. The share price at US$105.23 reflects a 90 day share price return decline of 8.6% and a 1 year total shareholder return of 14.84%, suggesting recent momentum has softened even as longer term holders have still come out ahead. If this kind...
NasdaqGS:MCHP
NasdaqGS:MCHPSemiconductor

Microchip Technology (MCHP) Is Up 15.4% After Raising Q3 Outlook And Deepening NVIDIA AI Ties

In early January 2026, Microchip Technology raised its fiscal third-quarter 2026 net sales outlook to about US$1,185 million, well above prior guidance, citing a broad-based recovery across most end markets and easing inventory corrections. A separate January 2026 announcement revealed custom firmware for Microchip’s MEC1723 embedded controller in NVIDIA’s DGX Spark personal AI supercomputers, underscoring the company’s push into secure, system-level management for AI workloads and advanced...
TSE:8058
TSE:8058Trade Distributors

Is Mitsubishi (TSE:8058) Overvalued After Strong 1 Year Returns And Recent Price Swings

Mitsubishi stock snapshot after recent price moves Recent price swings in Mitsubishi (TSE:8058) have caught investor attention, with the share price near ¥3,739 and mixed short term returns, including a 1 day decline alongside gains over the past week. See our latest analysis for Mitsubishi. Looking beyond the latest pullback, Mitsubishi’s recent 7 day share price return of 4.27% sits alongside a 1 year total shareholder return of 55.69%. This combination signals momentum that has been strong...
TSX:ATD
TSX:ATDConsumer Retailing

Will Food-Service And EV Charging Expansion Change Alimentation Couche-Tard's (TSX:ATD) Narrative?

In recent months, Alimentation Couche-Tard has highlighted its pricing discipline, tight cost control, and expansion into higher-margin food-service offerings and EV charging infrastructure across its global network. These operational updates, combined with ongoing share buybacks and acquisition activity, point to a company working to broaden its revenue mix while reinforcing efficiency across its store base. Next, we’ll examine how this emphasis on food-service growth and EV charging could...
NasdaqCM:GEVO
NasdaqCM:GEVOOil and Gas

How Gevo’s (GEVO) COO Succession Plan Could Reshape Its Operations-Led Investment Story

Gevo, Inc. announced that on January 5, 2026, longtime President and Chief Operating Officer Dr. Christopher M. Ryan notified the company of his plan to retire around June 5, 2026, with experienced agribusiness executive Greg Hanselman hired as Executive Vice President, Operations and Engineering and expected to step into the COO role. This leadership transition brings in an operations leader with deep plant-based ingredient and manufacturing experience that could influence how Gevo executes...
SEHK:1672
SEHK:1672Biotechs

Ascletis Pharma (SEHK:1672) Is Up 9.9% After FDA Clears ASC30 Phase II Diabetes Trial - What's Changed

Ascletis Pharma announced that it received U.S. FDA Investigational New Drug clearance for a 13-week Phase II trial of its oral small-molecule GLP-1 candidate ASC30 in type 2 diabetes, with enrollment planned to start in the first quarter of 2026. The clearance builds on prior Phase II obesity data in which ASC30 delivered dose-dependent weight loss and relatively favorable gastrointestinal tolerability, reinforcing its potential as an oral treatment option across major metabolic...